← Return to High anxiety regarding Reclast or Prolia decison for OP meds

Discussion
Comment receiving replies
@gently

mablin,
thanks for sewing with this thread.
The advantage of the absence of bisphosphonate would be that it allows PTH to build strong bone.
I also suspect that part of the added bone density with bisphosphonates has to be a measurement of the bisphosphonate itself. That might only matter when the TBS indicates structural abnormality. Resistance to osteoporotic vertebral fracture is more dependant upon the trabecular bone than the cortical bone.

Jump to this post


Replies to "mablin, thanks for sewing with this thread. The advantage of the absence of bisphosphonate would be..."

Thank you @gently for your reply. Effects of prior treatment of bisphosphonates especially fosamax on Forteo were well studied. As Reclast becomes a more frequently used bisphosphonate, the need is there to see its effect on subsequent anabolic treatments. I share your thoughts.

I’m here to exchange much needed information for those who search for them. Generally I like results from solid RCTs as basis for decision making, but in a pinch I will opt for a lesser known treatment modality, of course under the careful guidance of my physician. From time to time, however, good studies or information remain scarce for a particular treatment transition. Mayo connect is just a right place for us to share experiences as well as ideas.

The following is what I know about the interesting anabolic to anabolic sequencing:

Forteo/Tymlos to Evenity: no good studies that I could find, but we know some had done or are doing this, including a few members on this forum. Their shared experiences are precious to some of us.

The rarer yet curious sequence of Evenity to Forteo/Tymlos: I came across three cases so far. One acquaintance is doing Evenity to Forteo under the direction of a very fine bone researcher and clinician who publishes in top rated journals, with careful clinical and bone markers monitoring. Hope we could see case reports soon and clinical studies in the future.